Brokerages Anticipate Pulmonx Co. (NASDAQ:LUNG) Will Post Quarterly Sales of $13.71 Million

Equities research analysts forecast that Pulmonx Co. (NASDAQ:LUNGGet Rating) will post $13.71 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Pulmonx’s earnings, with estimates ranging from $13.40 million to $13.93 million. Pulmonx reported sales of $12.20 million during the same quarter last year, which indicates a positive year-over-year growth rate of 12.4%. The firm is expected to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Pulmonx will report full-year sales of $58.48 million for the current financial year, with estimates ranging from $57.10 million to $59.38 million. For the next financial year, analysts expect that the company will report sales of $90.25 million, with estimates ranging from $87.50 million to $94.03 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Pulmonx.

Pulmonx (NASDAQ:LUNGGet Rating) last posted its earnings results on Tuesday, May 3rd. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). The firm had revenue of $10.79 million for the quarter, compared to the consensus estimate of $9.26 million. Pulmonx had a negative return on equity of 26.08% and a negative net margin of 102.87%. The business’s revenue was up 16.7% on a year-over-year basis. During the same period last year, the company posted ($0.34) EPS.

A number of equities analysts have recently commented on LUNG shares. Morgan Stanley decreased their price target on shares of Pulmonx from $37.00 to $30.00 and set an “equal weight” rating on the stock in a report on Friday, February 25th. Wells Fargo & Company decreased their price target on shares of Pulmonx from $55.00 to $27.00 and set an “equal weight” rating on the stock in a report on Thursday, February 24th. Zacks Investment Research raised shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Wednesday, April 27th. Canaccord Genuity Group reduced their target price on shares of Pulmonx from $53.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, February 28th. Finally, Bank of America started coverage on shares of Pulmonx in a report on Wednesday, March 2nd. They set a “neutral” rating and a $28.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $36.71.

In other news, CEO Glendon E. French III sold 12,500 shares of the firm’s stock in a transaction dated Thursday, February 17th. The shares were sold at an average price of $27.22, for a total value of $340,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Glendon E. French III sold 1,132 shares of the firm’s stock in a transaction dated Tuesday, March 1st. The stock was sold at an average price of $25.91, for a total transaction of $29,330.12. The disclosure for this sale can be found here. Insiders have sold a total of 14,090 shares of company stock valued at $381,447 in the last three months. 12.56% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. purchased a new stake in shares of Pulmonx in the 4th quarter worth about $26,000. US Bancorp DE lifted its position in Pulmonx by 107.7% during the 3rd quarter. US Bancorp DE now owns 1,030 shares of the company’s stock valued at $37,000 after acquiring an additional 534 shares during the period. Nisa Investment Advisors LLC purchased a new position in Pulmonx during the 4th quarter valued at about $37,000. Emerald Advisers LLC purchased a new position in Pulmonx during the 1st quarter valued at about $50,000. Finally, Royal Bank of Canada lifted its position in Pulmonx by 113.1% during the 2nd quarter. Royal Bank of Canada now owns 1,839 shares of the company’s stock valued at $81,000 after acquiring an additional 976 shares during the period. 92.85% of the stock is owned by hedge funds and other institutional investors.

Pulmonx stock opened at $18.71 on Monday. The firm’s 50 day simple moving average is $23.97 and its 200 day simple moving average is $28.58. The company has a current ratio of 11.33, a quick ratio of 10.92 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $694.46 million, a PE ratio of -13.36 and a beta of 1.63. Pulmonx has a 1-year low of $15.06 and a 1-year high of $45.81.

Pulmonx Company Profile (Get Rating)

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

See Also

Get a free copy of the Zacks research report on Pulmonx (LUNG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pulmonx (NASDAQ:LUNG)

Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.